BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
| Revenue (TTM) | $10.32M |
| Gross Profit (TTM) | $-72.95M |
| EBITDA | $-101.47M |
| Operating Margin | -915.00% |
| Return on Equity | -26.00% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.27 |
| Book Value | $8.54 |
| Price-to-Book | 2.94 |
| Price-to-Sales (TTM) | 105.14 |
| EV/Revenue | 71.27 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 91.00% |
| Shares Outstanding | $44.45M |
| Float | $34.95M |
| % Insiders | 2.44% |
| % Institutions | 85.48% |
Volatility is currently contracting
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for near-term proof-of-concept studies, and the rationale for pursuing inflammation as a therapeutic target.
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk planned to initiate in mid-2026, with data anticipated by end of year Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME) planned to initiate in mid-2026, with data anticipated in mid-2027 Completed upsized follow-on public offering of $132.3 million EMERYVILLE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge” or, "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its first quarter 2026 financial results.
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that it will host an R&D Day webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor.
